MARKET

MIRA

MIRA

Mira Pharma
NASDAQ
0.5372
-0.0113
-2.06%
After Hours: 0.5189 -0.0183 -3.41% 19:11 11/02 EST
OPEN
0.5890
PREV CLOSE
0.5485
HIGH
0.5890
LOW
0.5301
VOLUME
132.20K
TURNOVER
--
52 WEEK HIGH
1.750
52 WEEK LOW
0.5101
MARKET CAP
22.57M
P/E (TTM)
-0.3892
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MIRA last week (1026-1030)?
Weekly Report · 16h ago
Mira Pharmaceuticals reports weight, fat reduction with SKNY-1 in obese mice
TipRanks · 4d ago
MIRA Pharmaceuticals Announces Its Data From Exploratory Pilot Of SKNY-1 Shows Reductions In Body Weight, Fat Mass
Benzinga · 4d ago
MIRA Pharmaceuticals, Inc. Reports Positive Proof-of-Concept Results for Oral SKNY-1 in Obese Mice
NASDAQ · 5d ago
MIRA unveils promising preclinical data for oral obesity drug
TipRanks · 5d ago
MIRA Pharmaceuticals Announces Initial Proof-Of-Concept Results From Pilot Study Of SKNY-1 For Obesity And Metabolic Disorders In A Diet-Induced Obesity Mouse Model; Study Demonstrated Statistically Significant Reductions In Body Weight And Fat Mass Following Oral Administration Of SKNY-1 Compared With Vehicle-Treated Controls
Benzinga · 5d ago
Weekly Report: what happened at MIRA last week (1019-1023)?
Weekly Report · 10/26 09:32
Analysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Lucid Diagnostics (LUCD) and MIRA Pharmaceuticals, Inc. (MIRA)
TipRanks · 10/25 10:40
More
About MIRA
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.

Webull offers Mira Pharmaceuticals Inc stock information, including NASDAQ: MIRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MIRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MIRA stock methods without spending real money on the virtual paper trading platform.